Rhythm Pharmaceuticals will host a June 13 webcast to discuss six-month interim data from its Phase 2 trial of setmelanotide in Prader-Willi syndrome patients. The company’s live call will feature CEO David Meeker and Dr. Jennifer Miller reviewing safety and efficacy readouts.
Rhythm Pharmaceuticals will host a live conference call and webcast on Saturday, June 13 at 9:00 a.m. ET/8:00 a.m. CT to discuss six-month interim results from its Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome. Presenters will include CEO David Meeker and Dr. Jennifer Miller, and the archived webcast will be available for 30 days.
The ongoing Phase 2 study evaluates setmelanotide’s impact on hyperphagia and weight change in Prader-Willi syndrome patients over six months, with primary assessments of safety, tolerability and hunger score reduction. Interim findings will guide dose optimization and inform the design of potential pivotal trials.
Setmelanotide is an MC4R agonist approved for genetic obesity disorders such as Bardet-Biedl syndrome, POMC and LEPR deficiencies, and acquired hypothalamic obesity in patients aged two years and older. Rhythm is also advancing investigational MC4R agonists bivamelagon and RM-718, plus a suite of small molecules targeting congenital hyperinsulinism.
